
Belite Bio, Inc: shareholders and insiders
Price
$127.38
November 20, 2026Market cap $5.0B
What Ploutos Investor adds for Belite Bio
Part of Ploutos Investor, €9.99 a month
- The full history: 6 fiscal years, from 2020
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Insiders and their shares
Purchases and sales by officers and directors from Apr 9, 2026 to Nov 16, 2026, from their own Form 4 filings.
Bought on the market
–
nobody
Sold on the market
$41M
5 people
From Nov 22, 2025 to Nov 22, 2026, the days the chart shows. Change its range and the figures follow.
How the sales were made, as a share of their value
- Under a set plan93%
- The rest7%
- Nov 12, 2026Hendrik Peter SchollChief Medical OfficerKind10b5-1
- Nov 12, 2026Hendrik Peter SchollChief Medical OfficerKind10b5-1
- Nov 12, 2026Hendrik Peter SchollChief Medical OfficerKind10b5-1
- Nov 12, 2026Hendrik Peter SchollChief Medical OfficerKind10b5-1
- Oct 29, 2026Hao-Yuan ChuangChief Financial OfficerKind
- Oct 29, 2026Yu-Hsin LinChief Executive OfficerKind
- Oct 1, 2026Hendrik Peter SchollChief Medical OfficerKind10b5-1
- Oct 1, 2026Hendrik Peter SchollChief Medical OfficerKind10b5-1
- Oct 1, 2026Hendrik Peter SchollChief Medical OfficerKind10b5-1
- Oct 1, 2026Hendrik Peter SchollChief Medical OfficerKind10b5-1
- Oct 1, 2026Hendrik Peter SchollChief Medical OfficerKind10b5-1
- Oct 1, 2026Hendrik Peter SchollChief Medical OfficerKind10b5-1
- Oct 1, 2026Hendrik Peter SchollChief Medical OfficerKind10b5-1
- Oct 1, 2026Hendrik Peter SchollChief Medical OfficerKind10b5-1
- Sep 24, 2026Wan-Shan ChenDirectorKind
- Sep 8, 2026Yu-Hsin LinChief Executive OfficerKind10b5-1
- Sep 8, 2026Yu-Hsin LinChief Executive OfficerKind10b5-1
- Sep 8, 2026Yu-Hsin LinChief Executive OfficerKind10b5-1
- Sep 8, 2026Yu-Hsin LinChief Executive OfficerKind10b5-1
- Sep 8, 2026Yu-Hsin LinChief Executive OfficerKind10b5-1
- Sep 8, 2026Hao-Yuan ChuangChief Financial OfficerKind10b5-1
- Sep 8, 2026Hao-Yuan ChuangChief Financial OfficerKind10b5-1
- Sep 8, 2026Hao-Yuan ChuangChief Financial OfficerKind10b5-1
- Sep 8, 2026Hao-Yuan ChuangChief Financial OfficerKind10b5-1
- Sep 8, 2026Hao-Yuan ChuangChief Financial OfficerKind10b5-1
| Date | Person | Kind | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Nov 12, 2026 | Hendrik Peter SchollChief Medical Officer | 10b5-1 | 500 | $162.04 | $81.0K | Form 4 |
| Nov 12, 2026 | Hendrik Peter SchollChief Medical Officer | 10b5-1 | 500 | $164.68 | $82.3K | Form 4 |
| Nov 12, 2026 | Hendrik Peter SchollChief Medical Officer | 10b5-1 | 500 | $166.82 | $83.4K | Form 4 |
| Nov 12, 2026 | Hendrik Peter SchollChief Medical Officer | 10b5-1 | 500 | $170.41 | $85.2K | Form 4 |
| Oct 29, 2026 | Hao-Yuan ChuangChief Financial Officer | 5,000 | – | – | Form 4 | |
| Oct 29, 2026 | Yu-Hsin LinChief Executive Officer | 5,000 | – | – | Form 4 | |
| Oct 1, 2026 | Hendrik Peter SchollChief Medical Officer | 10b5-1 | 200 | $163.63 | $32.7K | Form 4 |
| Oct 1, 2026 | Hendrik Peter SchollChief Medical Officer | 10b5-1 | 24 | $164.64 | $4.0K | Form 4 |
| Oct 1, 2026 | Hendrik Peter SchollChief Medical Officer | 10b5-1 | 120 | $165.49 | $19.9K | Form 4 |
| Oct 1, 2026 | Hendrik Peter SchollChief Medical Officer | 10b5-1 | 50 | $166.44 | $8.3K | Form 4 |
| Oct 1, 2026 | Hendrik Peter SchollChief Medical Officer | 10b5-1 | 78 | $167.59 | $13.1K | Form 4 |
| Oct 1, 2026 | Hendrik Peter SchollChief Medical Officer | 10b5-1 | 12 | $168.21 | $2.0K | Form 4 |
| Oct 1, 2026 | Hendrik Peter SchollChief Medical Officer | 10b5-1 | 14 | $169.36 | $2.4K | Form 4 |
| Oct 1, 2026 | Hendrik Peter SchollChief Medical Officer | 10b5-1 | 2 | $170.02 | $340 | Form 4 |
| Sep 24, 2026 | Wan-Shan ChenDirector | 13.8K | $0.44 | $6.1K | Form 4 | |
| Sep 8, 2026 | Yu-Hsin LinChief Executive Officer | 10b5-1 | 2,400 | $194.33 | $466.4K | Form 4 |
| Sep 8, 2026 | Yu-Hsin LinChief Executive Officer | 10b5-1 | 6,090 | $195.62 | $1.2M | Form 4 |
| Sep 8, 2026 | Yu-Hsin LinChief Executive Officer | 10b5-1 | 6,058 | $196.54 | $1.2M | Form 4 |
| Sep 8, 2026 | Yu-Hsin LinChief Executive Officer | 10b5-1 | 8,752 | $197.36 | $1.7M | Form 4 |
| Sep 8, 2026 | Yu-Hsin LinChief Executive Officer | 10b5-1 | 2,700 | $198.09 | $534.8K | Form 4 |
| Sep 8, 2026 | Hao-Yuan ChuangChief Financial Officer | 10b5-1 | 2,200 | $194.28 | $427.4K | Form 4 |
| Sep 8, 2026 | Hao-Yuan ChuangChief Financial Officer | 10b5-1 | 4,120 | $195.60 | $805.9K | Form 4 |
| Sep 8, 2026 | Hao-Yuan ChuangChief Financial Officer | 10b5-1 | 4,475 | $196.47 | $879.2K | Form 4 |
| Sep 8, 2026 | Hao-Yuan ChuangChief Financial Officer | 10b5-1 | 4,605 | $197.23 | $908.2K | Form 4 |
| Sep 8, 2026 | Hao-Yuan ChuangChief Financial Officer | 10b5-1 | 2,562 | $198.05 | $507.4K | Form 4 |
From the Form 4s insiders file with the SEC within two business days of each trade. Before Jun 17, 2026 the table lists open-market purchases and sales only (no grants, option exercises or tax withholding), from the SEC's quarterly data sets. The 10b5-1 mark comes from the form's own box (since April 2023) or from a footnote of the filing that names the plan, where there is one.
Major holders (over 5%)
Whoever comes to own more than 5% of a class of shares reports it to the SEC on Schedule 13D or 13G. Here is each holder's latest filing.
- Lin Bioscience International Ltd.Share of class53.7%
- Darwin Global Management, Ltd.with 2 more personsShare of class8.10%
| Holder | Kind of stake | Share of class | Shares | Filed | Filing |
|---|---|---|---|---|---|
| Lin Bioscience International Ltd. | 53.7% | 17.10M | Jan 21, 2025 | 13G | |
| Darwin Global Management, Ltd.with 2 more persons | 8.10% | 3.03M | Feb 17, 20262 filings since Dec 10, 2025 | 13G/A |
Fell to 5% or less (1)
Holders whose latest filing says they hold 5% or less. After it they need not file again, so what they hold today is not known.
- Yu-Hsin Lin3.10%May 14, 202613G/A
From the Schedule 13D and 13G filed with the SEC since Dec 18, 2024, when they became structured data. A holder who has filed nothing since then is not shown here. A 13D is updated within two business days of any material change, a 13G up to 45 days after the quarter of the change, so the shares are those of the filing. The large managers also appear in the 13Fs.
Well-known managers
Which of the about 30 investment managers we track held the shares at the quarter end, and what they changed from the quarter before.
- Duquesne (Druckenmiller)In the quarter
- Millennium Mgmt (Englander)In the quarter-24%
- Citadel Advisors (Griffin)In the quarter
- Point72 (Cohen)In the quarter-63%
- Renaissance TechnologiesIn the quarter-41%
| Manager | Shares | In the quarter | Value | % of their portfolio |
|---|---|---|---|---|
| Duquesne (Druckenmiller) | 106.1K | $18M | 0.43% | |
| Millennium Mgmt (Englander) | 375.1K | -24% | $64M | 0.05% |
| Citadel Advisors (Griffin) | – | – | 0.02% | |
| Point72 (Cohen) | 19.1K | -63% | $3.3M | 0.01% |
| Renaissance Technologies | 32.8K | -41% | $5.6M | 0.01% |
From the 13Fs managers file with the SEC up to 45 days after each quarter end. They show only long positions on that day, not short sales or what has changed since. No recent 13F: Pershing Square (Ackman), Scion (Burry).
Short sales in daily trading
How much of the shares that changed hands were short sales, in the off-exchange trades brokers report each day.
In the last 14 sessions, 70.9% of the shares in the reported trades were short sales, against 67.5% in the 14 before.
- Last 14 sessionsNov 3, 2026 – Nov 20, 2026
- 70.9%
- The 14 beforeOct 14, 2026 – Nov 2, 2026
- 67.5%
- Change
- +3.4 pts
- Short sales a dayon average, of 129.3K shares
- 91.6K
- More than atof 3,666 US-listed companies, same days
- 98%
- Median of alleight in ten from 34.4% to 63.9%
- 50.5%
- Short sales
- Oct 14, 2026: Short sales 42.3%
- Oct 15, 2026: Short sales 72.5%
- Oct 16, 2026: Short sales 70.2%
- Oct 19, 2026: Short sales 68.3%
- Oct 20, 2026: Short sales 71.5%
- Oct 21, 2026: Short sales 72%
- Oct 22, 2026: Short sales 62.4%
- Oct 23, 2026: Short sales 54.1%
- Oct 26, 2026: Short sales 59.6%
- Oct 27, 2026: Short sales 69.2%
- Oct 28, 2026: Short sales 57.2%
- Oct 29, 2026: Short sales 69.2%
- Oct 30, 2026: Short sales 79.5%
- Nov 2, 2026: Short sales 79.3%
- Nov 3, 2026: Short sales 80.4%
- Nov 4, 2026: Short sales 75.8%
- Nov 5, 2026: Short sales 60.4%
- Nov 6, 2026: Short sales 60.3%
- Nov 9, 2026: Short sales 77.1%
- Nov 10, 2026: Short sales 77.1%
- Nov 11, 2026: Short sales 84.9%
- Nov 12, 2026: Short sales 78.2%
- Nov 13, 2026: Short sales 74.9%
- Nov 16, 2026: Short sales 59.9%
- Nov 17, 2026: Short sales 61.4%
- Nov 18, 2026: Short sales 51.6%
- Nov 19, 2026: Short sales 51.2%
- Nov 20, 2026: Short sales 65.7%
This is not the number of shares sold short today: it measures short sales within each day's trading, and only trades made off the exchanges. Much of it is market makers, who sell shares they do not have to fill buyers' orders and cover soon after, so for a heavily traded stock the share is often around half. Shares held short, which are published twice a month, are not included here.
What the insiders hold
The shares each insider reports holding after their latest trade (Form 4), for those who traded on the market in the last three years.
- Hao-Yuan ChuangChief Financial OfficerDirectly210.3K
- Yu-Hsin LinChief Executive OfficerDirectly187.9K
- Wan-Shan ChenDirectorDirectly37.3K
- Hendrik Peter SchollChief Medical OfficerDirectly12.5K
| Person | Directly | Indirectly | After the trade of | Filing |
|---|---|---|---|---|
| Hao-Yuan ChuangChief Financial Officer | 210.3K | – | Oct 29, 2026 | Form 4 |
| Yu-Hsin LinChief Executive Officer | 187.9K | – | Oct 29, 2026 | Form 4 |
| Wan-Shan ChenDirector | 37.3K | – | Sep 24, 2026 | Form 4 |
| Hendrik Peter SchollChief Medical Officer | 12.5K | – | Nov 12, 2026 | Form 4 |
A lower bound: it counts only the 4 officers and directors with a market trade since Nov 23, 2023. Anyone who neither bought nor sold since is not here, whatever they hold. The share is against the share count on the latest 10-K's cover.
The ETFs that hold it
Which of the 349 US equity ETFs we track hold the stock, and at what weight, from the funds' N-PORT filings.
- SPEMState Street(R) SPDR(R) Portfolio Emerging Markets ETFWeight in the fund0.01%
- ONEQFidelity Nasdaq Composite Index ETFWeight in the fund0.01%
| ETF | Weight in the fund | Holdings as of |
|---|---|---|
| SPEMState Street(R) SPDR(R) Portfolio Emerging Markets ETF | 0.01% | Jun 30, 2026 |
| ONEQFidelity Nasdaq Composite Index ETF | 0.01% | Aug 31, 2026 |
2 of the 349 ETFs we track, not of every ETF on the market. The ten largest weights. Positions as each fund filed them in its latest N-PORT.
Institutional investors by quarter
Every manager that reports positions to the SEC (Form 13F), quarter by quarter: how many hold the stock, how many shares and dollars between them, and who entered, left, added or trimmed during the quarter.
- Managers
- Q3 2025: Managers 34
- Q4 2025: Managers 69
- Q1 2026: Managers 75
- Q2 2026: Managers 81
Institutional investors by quarter
The fund managers holding BLTE, quarter by quarter, from Q2 2022 to Q2 2025, 13 more quarters
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 12 quarters.
Q2 2026: 81 managers held 9.47M shares, worth $1.4B. During the quarter 22 opened a position, 16 closed one, 28 added and 22 trimmed.
The largest holders, Q2 2026
- Darwin Global ManagementIn the quarter+0.6%
- Paradigm Biocapital AdvisorsIn the quarter+11%
- Rtw InvestmentsIn the quarter
- Millennium Mgmt (Englander)In the quarter-13%
- Maverick CapitalIn the quarter
- Eventide Asset ManagementIn the quarter+9.3%
- Deerfield ManagementIn the quarter+17%
- Holocene AdvisorsIn the quarter-49%
- Logos Global ManagementIn the quarter
- Morgan StanleyIn the quarter+17%
| Manager | Shares | In the quarter | Value |
|---|---|---|---|
| Darwin Global Management | 3.08M | +0.6% | $457M |
| Paradigm Biocapital Advisors | 1.23M | +11% | $190M |
| Rtw Investments | 715.3K | $110M | |
| Millennium Mgmt (Englander) | 494.6K | -13% | $76M |
| Maverick Capital | 396.3K | $61M | |
| Eventide Asset Management | 390.8K | +9.3% | $60M |
| Deerfield Management | 357.2K | +17% | $55M |
| Holocene Advisors | 251.0K | -49% | $39M |
| Logos Global Management | 250.0K | $38M | |
| Morgan Stanley | 235.1K | +17% | $36M |
From the SEC's Form 13F data sets, Q3 2025 to Q2 2026: the long positions of every manager with more than $100 million under management, as filed up to 45 days after each quarter end. Short positions and options are not in them. Shares as reported each quarter, not adjusted for splits. The stock is matched by its CUSIP, through the SEC's fails-to-deliver files.
Pay against performance, the say-on-pay vote, buybacks by quarter and trading plans are read for S&P 500 companies only.
The full analysis
What do Belite Bio's filings show?
Who buys and sells is one part of Belite Bio's picture. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Have BLTE's insiders bought or sold?
From Jun 17, 2026 to Nov 16, 2026 Belite Bio's insiders bought 0 and sold $35M of shares on the market. 92% of the sales were under set 10b5-1 plans.
Which well-known managers hold BLTE?
5 of the managers we track held the shares on Sep 30, 2026. The largest position was Millennium Mgmt (Englander)'s, worth $64M.
Is every insider transaction a purchase or a sale?
No. Many are part of their pay: share awards, option exercises and shares the company keeps for the tax. Only code P is a purchase with their own money, and code S a sale on the market.
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.